| Johnson & Johnson (JNJ) | |||
|---|---|---|---|
| 239.08 7.79 (3.37%) | 06-23 16:00 | ||
| Open: | 236.375 | Pre. Close: | 231.29 |
| High: | 239.79 | Low: | 234.35 |
| Volume: | 7,590,889 | Market Cap: | 575,517(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 282.19 One year: 329.60 |
| Support: | Support1: 228.77 Support2: 220.84 |
| Resistance: | Resistance1: 241.60 Resistance2: 282.19 |
| Pivot: | 233.18 |
| Moving Averages: | MA(5): 233.63 MA(20): 231.94 MA(100): 234.13 MA(250): 204.11 |
| MACD: | MACD(12,26): 1.72 Signal(12,26,9): 1.56 |
| %K %D: | %K(14,3): 58.12 %D(3): 55.03  |
| RSI: | RSI(14): 59.45 |
| 52-Week: | High: 251.71 Low: 150.73 Change(%): 61.0 |
| Average Vol(K): | 3-Month: 7805 10-Days: 8823 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 240.198 - 241.345 | 241.345 - 242.387 |
| Low: | 231.498 - 232.846 | 232.846 - 234.069 |
| Close: | 236.857 - 239.075 | 239.075 - 241.088 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ JNJ ] has closed below upper band by 22.5%. Bollinger Bands are 32.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - General | |
| Shares Out. (M) | 2410.00 |
| Shares Float (M) | 2400.00 |
| % Held by Insiders | 0.05 |
| % Held by Institutions | 76.83 |
| Shares Short (K) | 23410 |
| Shares Short Prior Month (K) | 22350 |
| Stock Financials | |
|---|---|
| EPS | 8.620 |
| Book Value (p.s.) | 33.740 |
| Profit Margin | 21.83 |
| Operating Margin | 27.41 |
| Return on Assets (ttm) | 8.4 |
| Return on Equity (ttm) | 26.4 |
| Qtrly Rev. Growth | 9.9 |
| Gross Profit (p.s.) | 27.203 |
| Sales Per Share | 39.983 |
| EBITDA (p.s.) | 14.245 |
| Qtrly Earnings Growth | -52.90 |
| Operating Cash Flow (M) | 22870.00 |
| Levered Free Cash Flow (M) | 12510.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | 27.74 |
| PEG Ratio | 3.13 |
| Price to Book value | 7.09 |
| Price to Sales | 5.98 |
| Price to Cash Flow | 25.19 |
| Stock Dividends | |
|---|---|
| Dividend | 1.340 |
| Dividend Yield | 0.01 |
| Dividend Growth | |
